Armin Ghobadi, MD

Blood and Marrow Transplant & Cellular/Gene Therapy Specialist, Hematologic Oncologist, Medical Oncologist

Armin Ghobadi

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Armin Ghobadi, MD

Watch video on YouTube

Armin Ghobadi, MD

3 mins

Washington University bone marrow transplant specialist and medical oncologist Armin Ghobadi, MD, discusses what leukemia, lymphoma and bone marrow transplant patients can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Ghobadi: https://siteman.wustl.edu/doctor/ghobadi-armin/

Explore the Blood and Marrow Transplant Program at Siteman Cancer Center: https://siteman.wustl.edu/treatment/specialized-programs/stem-cell-transplant-and-cellular-therapies-center/blood-and-marrow-transplant-program/

Researchers at Washington University School of Medicine have developed a method for stem cell transplantation that doesn't require radiation or chemotherapy. Learn more: https://siteman.wustl.edu/new-technique-may-lead-to-safer-stem-cell-transplants/

Interested in becoming a donor? Learn more: https://siteman.wustl.edu/treatment/specialized-programs/stem-cell-transplant-and-cellular-therapies-center/blood-and-marrow-transplant-program/for-donors/

Clinical Expertise

  • As a member of our leukemia and lymphoma specialist teams, Dr. Ghobadi cares for patients diagnosed with leukemia and lymphoma through treatment and recovery.

Primary Academic Title

Professor of Medicine, Division of Medical Oncology, Section of Bone Marrow Transplant, WashU Medicine

Board Certification

  • 2009: American Board of Internal Medicine
  • 2013: American Board of Internal Medicine, Hematology
  • 2014: American Board of Internal Medicine, Medical Oncology

Training

  • 2006 - 2007: Intern, Internal Medicine, University of Texas Southwestern School of Medicine, Dallas, TX
  • 2007 - 2009: Resident, University of Texas Southwestern School of Medicine, Dallas, TX
  • 2009 - 2012: Fellow, Hematology and Oncology, WashU Medicine, St. Louis, MO
  • 2012 - 2014: Fellow, Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

Education

  • 2001: MD, University of Medical Sciences and Health Services, Tehran, Iran

Research & Select Publications

Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Pro…
Authors:

Ghobadi A, Anagnostou T, Azzi J, one or more additional authors omitted Pasquini MC

Journal & Year:

Transplant Cell Ther | 2026

Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy
Authors:

Cochran HC, Ghobadi KA, Ghobadi A

Journal & Year:

Immunotherapy | 2025

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
Authors:

Ghobadi A, Aldoss I, Maude SL, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma
Authors:

Nizamuddin IA, Ghobadi A

Journal & Year:

Am Soc Clin Oncol Educ Book | 2025

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Authors:

Shah BD, Cassaday RD, Park JH, one or more additional authors omitted Ghobadi A, Oluwole OO

Journal & Year:

Leukemia | 2025

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted Ghobadi A, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial
Authors:

Ghobadi A, Caimi PF, Reese JS, one or more additional authors omitted de Lima M

Journal & Year:

EClinicalMedicine | 2025

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
Authors:

Ghobadi A, Bachanova V, Patel K, one or more additional authors omitted Strati P

Journal & Year:

Lancet | 2025

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
Authors:

Roddie C, Sandhu KS, Tholouli E, one or more additional authors omitted Ghobadi A, one or more additional authors omitted Jabbour E

Journal & Year:

N Engl J Med | 2024

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Authors:

Jain MD, Spiegel JY, Nastoupil LJ, one or more additional authors omitted Ghobadi A, one or more additional authors omitted Dahiya S

Journal & Year:

J Clin Oncol | 2024

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial
Authors:

Ghobadi A, Aldoss I, Maude S, one or more additional authors omitted DiPersio J

Journal & Year:

Res Sq | 2024

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Authors:

Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, one or more additional authors omitted Pasquini MC

Journal & Year:

Blood | 2024

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Authors:

Ghobadi A, Munoz J, Westin JR, one or more additional authors omitted Oluwole OO

Journal & Year:

Blood Adv | 2024

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma a…
Authors:

Lunning MA, Wang HL, Hu ZH, one or more additional authors omitted Ghobadi A, one or more additional authors omitted Pasquini MC

Journal & Year:

Am J Hematol | 2024

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failur…
Authors:

Mahadeo KM, Baiocchi R, Beitinjaneh A, one or more additional authors omitted Ghobadi A, one or more additional authors omitted Prockop S

Journal & Year:

Lancet Oncol | 2024